Want to see CVKD full AI Analyst Report?
Cadrenal Therapeutics, Inc. (CVKD) Financial Statements
Cadrenal Therapeutics, Inc. Financial Overview
Cadrenal Therapeutics, Inc.'s market cap is currently $3.51M. The company's EPS TTM is $-4.90; its P/E ratio is -0.20; Cadrenal Therapeutics, Inc. is scheduled to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.91. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Dec 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|
| Income Statement | ||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -1.88K | $ 0.00 | $ -1.27K |
| Operating Income | $ -13.46M | $ -10.96M | $ -7.63M | $ -2.70M |
| EBITDA | $ -13.23M | $ -10.65M | $ -8.34M | $ -6.61M |
| Net Income | $ -13.24M | $ -10.65M | $ -8.36M | $ -6.71M |
| Balance Sheet | ||||
| Cash & Short-Term Investments | $ 4.01M | $ 10.02M | $ 8.40M | $ 32.59K |
| Total Assets | $ 4.33M | $ 10.12M | $ 8.52M | $ 778.17K |
| Total Debt | $ 0.00 | $ 0.00 | $ 21.35K | $ 640.71K |
| Net Debt | $ -4.01M | $ -10.02M | $ -8.38M | $ 608.12K |
| Total Liabilities | $ 1.59M | $ 2.68M | $ 826.88K | $ 6.33M |
| Stockholders' Equity | $ 2.74M | $ 7.44M | $ 7.69M | $ -5.55M |
| Cash Flow | ||||
| Free Cash Flow | $ -12.60M | $ -7.36M | $ -3.53M | $ -1.32M |
| Operating Cash Flow | $ -12.60M | $ -7.36M | $ -3.53M | $ -1.31M |
| Investing Cash Flow | $ -5.10K | $ -6.54K | $ -3.25K | $ -2.49K |
| Financing Cash Flow | $ 6.60M | $ 8.98M | $ 11.90M | $ 1.35M |
Currency in USD